BackBiondvax Pharmaceuticals Overview

Biondvax Pharmaceuticals Selling, General & Admin

Selling, General & Admin expenses for BVXV.

Quarterly SG&A Expenses

$1.14M
↓ 73.38% YoY

As of Jun 30, 2023

Annual SG&A Expenses (TTM)

$7.53M
↓ 65.6% YoY

Trailing 12 months ending Jun 30, 2023

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin